GUFICBIOGufic Biosciences Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 0.5 this quarter.
Momentum from moving averages, Supertrend and RSI.
4 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
4 found · risk severe
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹288 Cr | ₹23 Cr | 14.14% | 8.14% | ₹2.34 | 4.0x |
| Q1 FY2027 | ₹261 Cr | ₹22 Cr | 14.91% | 8.55% | ₹2.22 | 4.2x |
| Q4 FY2026 | ₹252 Cr | ₹22 Cr | 15.71% | 8.69% | ₹2.18 | 4.1x |
| Q3 FY2026 | ₹231 Cr | ₹12 Cr | 10.92% | 5.37% | ₹1.24 | 3.1x |
| Q2 FY2026 | ₹237 Cr | ₹17 Cr | 12.69% | 7.10% | ₹1.68 | 3.4x |
| Q1 FY2026 | ₹224 Cr | ₹13 Cr | 11.43% | 5.84% | ₹1.30 | 2.9x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.